Preclinical Immunogenicity Assessment

BioProcess International

Home | Downstream | Upstream | Manufacturing | Archive

Webcast Information

Preclinical Immunogenicity Assessment

Protein therapeutics can potentially elicit immune responses when administered in humans. These antidrug antibodies could result in partial or complete loss of drug efficacy and other complications that have the potential to cause severe adverse effects in the patient. In this webcast, Philippe Stas, Head of Applied Protein Services at Lonza, discusses the benefits of preclinical immunogenicity assessment, including:

Early-stage Risk Assessment
Improved Quality and Safety of Drugs
Reduced Attrition Rate in Drug Development Programs

View this webcast to learn more about managing drug-induced immune responses at the earliest possible stage to produce safer and more cost-effective protein therapeutics.

Targeted BPI Content

Measuring Manufacturing Cost and Its Impact on Organizations
BioProcess International, June 2010
Read more.

How Geography Affects the Cost of Biomanufacturing
BioProcess International, June 2010
Read more.

Flexible Manufacturing
BioProcess International, May 2010
Read more.

A Smarter Approach to Biomanufacturing
BioProcess International, May 2010
Read more.

Road Map to Implementation of Single-Use Systems
BioProcess International, April 2010
Read more.

Changes in Raw Material Sources from Suppliers
BioProcess International, April 2010
Read more.

Delivering Affordable Biologics from Gene to Vial
BioProcess International, March 2010
Read more.